Phase1/2 Study of Vaccination With CDCA1 Derived Epitope Peptide for HLA-A24-positive Patients With Advanced Prostate Cancer
Cell division cycle associated gene 1(CDCA1) has been identified using genome-wide
expression profile analysis by the use of cDNA microarray in our previous studies. We have
determined the HLA-A*2402 restricted epitope peptides derived from CDCA1, CDCA1-A24-56. This
epitope showed strong IFN-g production when stimulated with the appropriate targets
expressed the appropriate protein and HLA-A*2402. Furthermore, when vaccinated this peptide,
specific CTL was determined after the vaccination. Therefore we focused on the safety and
efficacy of novel vaccination for the advanced prostate cancer patients who already showed
resistance to standard hormonal therapy and chemotherapy.
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
feasibility (toxicities as assessed by NCI-CTCAE version 3)
2 years
Yes
Tomoaki Fujioka, MD, PhD
Study Chair
Department of Urology, Iwate Medical University
Japan: Ministry of Health, Labor and Welfare
IMU-H21-40-PⅠ/Ⅱ
NCT01225471
June 2009
May 2012
Name | Location |
---|